NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00803049

CompletedPhase 3

Sponsor: Sanofi

Conditions: Multiple Sclerosis

Interventions: Teriflunomide (HMR1726)

Countries: United States, Austria, Canada, Chile, Czechia, Denmark, Estonia, Finland

The primary objective of this study was to document the long-term safety and tolerability of teriflunomide in Multiple Sclerosis (MS) participants with relapse. The secondary objective was to document the long-term efficacy on disability progression, relapse rate and Magnetic Resonance Imaging (MRI) parameters.

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participant who completed the previous double-blind placebo-controlled study EFC6049 and who did not meet criteria for treatment withdrawal.
* Willingness to participate in a long-term safety/efficacy trial.

Exclusion Criteria:

* Any known condition or circumstance that would prevent in the investigator's opinion, compliance or completion of the study.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Locations (116)

Maitland, Florida, United States
Fort Wayne, Indiana, United States
Detroit, Michigan, United States
Allentown, Pennsylvania, United States
Graz, Austria
Innsbruck, Austria
Vienna, Austria
Vienna, Austria
Calgary, Canada
Gatineau, Canada
Greenfield Park, Canada
Halifax, Canada
London, Canada
Montreal, Canada
Ottawa, Canada
Québec, Canada
St. John's, Canada
Toronto, Canada
Vancouver, Canada
Winnipeg, Canada
Santiago, Chile
Santiago, Chile
Santiago, Chile
Santiago, Chile
Viña del Mar, Chile
Olomouc, Czechia
Glostrup Municipality, Denmark
Sønderborg, Denmark
Vejle, Denmark
Tallinn, Estonia
+ 86 more on CT.gov